ArticleThe Journal of biological chemistry2016
3'-NADP and 3'-NAADP, Two Metabolites Formed by the Bacterial Type III Effector AvrRxo1.
Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- NAADP-Mediated CaHandbook of experimental pharmacology · 2023Article
- The bacterial effector AvrRxo1 inhibits vitamin B6 biosynthesis to promote infection in rice.Plant communications · 2022Article
- Tal2c Activates the Expression ofInternational journal of molecular sciences · 2021Article
- A bacterial kinase phosphorylates OSK1 to suppress stomatal immunity in rice.Nature communications · 2021Article
- What the Wild Things Do: Mechanisms of Plant Host Manipulation by Bacterial Type III-Secreted Effector Proteins.Microorganisms · 2021Review
- Enzymatic Functions for Toll/Interleukin-1 Receptor Domain Proteins in the Plant Immune System.Frontiers in genetics · 2020Review
- Integration of nicotinic acid adenine dinucleotide phosphate (NAADP)-dependent calcium signalling.The Journal of physiology · 2018Review
- The ng_ζ1 toxin of the gonococcal epsilon/zeta toxin/antitoxin system drains precursors for cell wall synthesis.Nature communications · 2018Article
- Plant Responses to Pathogen Attack: Small RNAs in Focus.International journal of molecular sciences · 2018Review
- A bacterial toxin-antitoxin module is the origin of inter-bacterial and inter-kingdom effectors of Bartonella.PLoS genetics · 2017Article
- Foundational and Translational Research Opportunities to Improve Plant Health.Molecular plant-microbe interactions : MPMI · 2017Article
- The effector AvrRxo1 phosphorylates NAD in planta.PLoS pathogens · 2017Article
- Article
- The Importance of the Expendable: Toxin-Antitoxin Genes in Plasmids and Chromosomes.Frontiers in microbiology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An arsenal of effector proteins is injected by bacterial pathogens into the host cell or its vicinity to increase virulence. The commonly used top-down approaches inferring the toxic mechanism of individual effector proteins from the host's phenotype are often impeded by multiple targets of different effectors as well as by their pleiotropic effects. Here we describe our bottom-up approach, showing that the bacterial type III effector AvrRxo1 of plant pathogens is an authentic phosphotransferase that produces two novel metabolites by phosphorylating nicotinamide/nicotinic acid adenine dinucleotide at the adenosine 3'-hydroxyl group. Both products of AvrRxo1, 3'-NADP and 3'-nicotinic acid adenine dinucleotide phosphate (3'-NAADP), are substantially different from the ubiquitous co-enzyme 2'-NADP and the calcium mobilizer 2'-NAADP. Interestingly, 3'-NADP and 3'-NAADP have previously been used as inhibitors or signaling molecules but were regarded as "artificial" compounds so far. Our findings now necessitate a shift in thinking about the biological importance of 3'-phosphorylated NAD derivatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.